Format

Send to

Choose Destination
Curr Cardiol Rep. 2019 Mar 18;21(5):34. doi: 10.1007/s11886-019-1122-z.

PET/CT for Diagnosis and Management of Large-Vessel Vasculitis.

Author information

1
Department of Medical Imaging, Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada.
2
Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
3
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. TRuddy@ottawaheart.ca.

Abstract

PURPOSE OF REVIEW:

This review aims to discuss the use of fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) for diagnosis and management of patients with large-vessel vasculitis (LVV).

RECENT FINDINGS:

Incidence of LVV is likely underestimated, in part due to its non-specific symptoms. Nevertheless, early diagnosis of LVV is essential to initiate timely therapy in order to prevent vascular complications, such as stenoses and aneurysms. FDG PET/CT imaging has the ability to detect LVV during the acute phase, prior to edema and other vascular structural changes, with its high sensitivity for inflammatory activity. FDG PET/CT was shown to be a powerful prognostic marker by allowing identification of patients at risk of vascular complications. Additionally, preliminary data support the use of FDG PET/CT to follow therapy efficacy. FDG PET/CT allows early detection of inflammation, before morphological and irreversible vascular changes can be observed, allowing prompt diagnosis and treatment of LVV.

KEYWORDS:

FDG; Fluorodeoxyglucose; Giant cell arteritis (GCA); Large-vessel vasculitis; Positron emission tomography; Takayasu’s arteritis

PMID:
30887249
DOI:
10.1007/s11886-019-1122-z

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center